## ADPT: Adaptive Biotechnologies Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($14.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($1.31M) |
| Sells | 13 ($5.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.18) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_10 falling (-2.3% 5d) with bearish MACD, trend may be turning.
3. Insider selling cluster: $5.6M in recent transactions.
4. Elevated short interest (8.2%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Insider selling cluster ($5.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.5B |
| Beta | 2.18 |
| 52W Range | $5.97 - $20.76 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from -0.2% to -2.4% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.4pp (needs >3.0% for momentum thesis). RSI neutral at 48. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.42% (CS: 12) | Weak |
| RSI_14 | 47.6 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.980x | Below |
| vs SMA200 | 1.302x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $16.17
- **Stop Loss:** $14.45 (10.6% risk)
- **Target:** $17.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 501
- **Position Value:** $8,101.17
- **Portfolio %:** 8.10%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*